A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Eisai Inc.
Eisai Inc.
Eli Lilly and Company
SAPU NANO (US) LLC
Eli Lilly and Company
Boehringer Ingelheim
Kyowa Kirin Co., Ltd.
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Novartis
Gilead Sciences
Novartis
Pfizer
Taizhou EOC Pharma Co., Ltd.